Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Akari Therapeutics Plc | Director | Ordinary Shares, par value $0.0001 per share | 3.66B | May 31, 2024 | Direct | ||
Akari Therapeutics Plc | Director | Warrants (Right to Buy) | 1.33B | May 31, 2024 | Direct | ||
Akari Therapeutics Plc | Director | Ordinary Shares, par value $0.0001 per share | 801M | May 31, 2024 | RPC Pharma Limited | ||
Akari Therapeutics Plc | Director | Ordinary Shares, par value $0.0001 per share | 38.7M | May 31, 2024 | Praxis Trustees Limited | ||
Akari Therapeutics Plc | Director | Stock Option (Right to Buy) | 10M | Jun 28, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
AKTX | Akari Therapeutics Plc | Jun 28, 2024 | 1 | $0 | 4 | Jul 2, 2024 | Director |
AKTX | Akari Therapeutics Plc | May 31, 2024 | 2 | $2.39M | 4 | Jun 4, 2024 | Director |
AKTX | Akari Therapeutics Plc | Jan 1, 2024 | 0 | $0 | 3 | Jan 2, 2024 | Director |